Novo Nordisk’s Wegovy Drug Sales Miss Expectations
The Danish pharmaceutical company’s blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter ...
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
How South Florida patients are fighting for access to drugs like Ozempic, Wegovy and Mounjaro
CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...
Americans split on using weight loss drugs to treat obesity: Survey
Americans are split on using weight loss drugs such as Ozempic and Wegovy to treat obesity or weight-related conditions, ...
About half of Americans approve of using weight-loss drugs to treat obesity, AP-NORC poll finds
A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a ...
Wegovy obesity drug sales more than double but set to slow
Sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner (£2.2 billion) in the fourth ...
Healthy Returns: Why people quit weight loss, diabetes drugs within one year
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
Is Compounded Semaglutide Effective for Weight Loss?
Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
Wegovy sales double to boost Novo Nordisk's fourth quarter but slower growth predicted
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...
The Motley Fool3d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
And based on the data so far, amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight loss was ...